Bioidentical Hormone Therapy for Women and Men

At HormoneSynergy®, hormone therapy is part of an individualized longevity medicine approach rather than a standardized protocol.

Hormones influence reproductive function, bone, muscle, sleep, sexual health, mood, body composition, and many aspects of metabolism. Changes in estradiol, progesterone, or testosterone can produce clinically meaningful symptoms in appropriately selected women and men, but symptoms should be interpreted within the larger medical picture.

Fatigue, poor sleep, weight change, brain fog, low libido, loss of strength, or mood changes are not specific to hormone deficiency. Thyroid disease, anemia, sleep apnea, insulin resistance, medications, depression, cardiovascular disease, calorie restriction, alcohol use, and other medical conditions can produce similar complaints.

If you are looking for a more complete physician-led evaluation, you can request a hormone evaluation here.

What Are Bioidentical Hormones?

Bioidentical hormones have the same molecular structure as hormones produced naturally in the human body. Common examples include 17β-estradiol, micronized progesterone, and testosterone.

The word bioidentical is frequently confused with compounded, but the terms are not interchangeable. Many FDA-approved prescription products contain hormones that are structurally identical to endogenous human hormones. Estradiol patches, gels, sprays, vaginal preparations, and oral micronized progesterone are examples.

Custom-compounded hormone preparations can also contain bioidentical hormones. Compounding may be appropriate when available commercial products do not adequately meet an individual patient's clinical needs, preferred route, dosing requirements, tolerability, or treatment plan.

Compounded preparations do not undergo the same FDA premarket review as commercially approved products. That distinction should be discussed with patients as part of informed decision-making rather than used to suggest that every compounded therapy is either preferable or inappropriate.

Bioidentical Hormone Therapy for Women

Menopausal hormone therapy can be considered for women experiencing clinically significant symptoms or other recognized indications related to the menopausal transition.

Common reasons women discuss hormone therapy include:

• Hot flashes and night sweats
• Menopause-related sleep disruption
• Genitourinary syndrome of menopause
• Vaginal dryness or discomfort
• Bone-health concerns in appropriate patients
• Premature ovarian insufficiency or early menopause
• Sexual-health concerns
• Quality-of-life effects associated with the menopausal transition

Systemic hormone therapy can be delivered through several routes. Some women prefer a transdermal patch or gel, some use oral medication, some require local vaginal treatment, and some prefer compounded or implanted approaches after reviewing the advantages and limitations of those options with their physician.

Women who have a uterus and use systemic estrogen generally require adequate progesterone or another progestogen to reduce the risk of endometrial hyperplasia and endometrial cancer.

Our article Progesterone Is Not Just “The Sleep Hormone” explains the role of progesterone and endometrial protection in more detail.

What Changed With Menopausal Hormone Therapy in 2026?

The regulatory discussion surrounding menopausal hormone therapy changed substantially in 2026.

On February 12, 2026, the FDA approved labeling changes for an initial group of menopausal hormone therapy products that removed boxed-warning statements related to cardiovascular disease, breast cancer, and probable dementia. The action followed a broader reassessment of the evidence surrounding menopausal hormone therapy.

The labeling change did not establish that hormone therapy is risk-free or appropriate for every woman. Risks and benefits remain influenced by age, medical history, timing, route, formulation, dose, uterus status, breast-health history, thrombotic risk, metabolic health, and other clinical factors.

The change does reinforce the importance of distinguishing among different women, different formulations, different routes, and different clinical indications rather than treating menopausal hormone therapy as a single uniform exposure.

Estrogen, Menopause, and Brain Health

Brain health has become an increasingly important part of the menopause discussion. Estradiol receptors are found in regions involved in memory, mood, sleep, vascular regulation, neuronal signaling, and cerebral metabolism.

Research published in 2026 has added to the evidence linking menopause timing and estrogen exposure with later brain health. An observational Neurology study found lower odds of greater Alzheimer-related neuropathology among women who reported estrogen-only menopausal hormone therapy. A large UK Biobank analysis also reported lower adjusted dementia risk among women who had used menopausal hormone therapy, with stronger associations in certain subgroups and among women beginning therapy closer to menopause.

These findings are encouraging but do not establish menopausal hormone therapy as a proven dementia-prevention treatment. A larger systematic review published in 2025 found no significant overall increase or decrease in dementia risk associated with menopausal hormone therapy.

For the larger cognitive-health framework, see Brain Health & Cognitive Longevity and Menopause and Brain Health: The Complete Guide.

Testosterone Therapy for Women

Testosterone has physiologic roles in women as well as men. The evidence for systemic testosterone therapy in women is strongest for appropriately evaluated women with hypoactive sexual desire disorder, although clinicians also encounter women with broader symptoms and treatment histories that require individualized evaluation.

There is currently no FDA-approved testosterone product specifically formulated for women in the United States. Treatment therefore requires careful attention to dose, route, symptoms, laboratory values when appropriate, clinical response, and potential androgenic effects.

Available delivery methods may include carefully dosed transdermal preparations, compounded formulations, and implanted pellets. These routes should not be viewed as interchangeable. Each has practical advantages and limitations involving convenience, dose flexibility, absorption, adherence, reversibility, duration of action, and monitoring.

Pellet Therapy for Women at HormoneSynergy®

HormoneSynergy® continues to offer pellet therapy as one hormone-delivery option for appropriately selected women.

Dr. Kathryn Retzler has provided pellet therapy for women for many years and has substantial clinical experience with patient selection, dosing, insertion technique, monitoring, symptom response, and management over time. That experience is relevant because pellet therapy requires familiarity with its pharmacology and with the practical differences between an implanted preparation and a medication that can be adjusted or discontinued more quickly.

Pellets may appeal to women who prefer a longer-duration delivery system and who do not want to apply a gel, change a patch, take a daily oral medication, or use another more frequent dosing schedule. For a woman who has previously responded well to pellet therapy, convenience and consistency may also influence her preference.

The tradeoff is that an implanted pellet is intended to dissolve gradually and cannot be adjusted from day to day after insertion. This makes appropriate patient selection, conservative dosing, informed consent, and follow-up particularly important.

ACOG's current guidance recommends testosterone preparations other than pellets for women because long-term safety data remain limited and pellets cannot be readily removed after implantation. The same guidance also acknowledges published evidence showing improvement in menopausal symptom scores with implanted testosterone. HormoneSynergy® discusses those limitations and the available evidence with women considering pellet therapy rather than treating the route as either universally preferable or categorically inappropriate.

Dr. Retzler's clinical experience with pellet therapy informs how this option is used at HormoneSynergy®. Clinical experience does not replace published evidence or remove the uncertainties associated with any treatment route, but it is relevant to individualized patient selection, dosing, monitoring, recognition of adverse effects, and shared decision-making.

Women who prefer pellets can therefore discuss them alongside transdermal, oral, vaginal, injectable, and other compounded or commercially available options. The objective is to select the delivery method that best fits the woman's clinical indication, treatment history, preferences, risk profile, and response to therapy.

Testosterone Therapy for Men

Testosterone therapy can be appropriate for men with clinically established hypogonadism. The diagnosis should not be based on fatigue, low motivation, weight gain, or age alone because these symptoms have many possible causes.

The Endocrine Society recommends diagnosing male hypogonadism when a man has symptoms or signs consistent with testosterone deficiency together with unequivocally and consistently low testosterone concentrations. Testosterone is generally confirmed with at least two early-morning measurements using an appropriate laboratory method.

When treatment is appropriate, testosterone may improve symptoms associated with androgen deficiency, including sexual symptoms and, in selected patients, effects on lean mass, bone, anemia, or well-being.

Monitoring remains important. Depending on age and clinical circumstances, this can include testosterone concentrations, hematocrit, treatment response, adverse effects, prostate assessment when indicated, fertility goals, and evaluation of cardiovascular and sleep-apnea risk.

Read more: Testosterone Therapy for Men Over 40: A Longevity Medicine Perspective.

FDA-Approved Hormones and Compounded Hormones

FDA-approved bioidentical hormones and compounded bioidentical hormones have different regulatory and manufacturing frameworks, although both may have roles in clinical practice.

FDA-approved products have standardized dosing, manufacturing oversight, pharmacokinetic information, and safety and effectiveness data for approved indications. Compounded preparations allow additional flexibility when an individual patient needs a dose, combination, ingredient profile, or delivery method that is not available commercially.

ACOG recommends FDA-approved menopausal hormone products when suitable formulations meet the patient's needs because compounded preparations have less standardized safety, efficacy, potency, and pharmacokinetic data.

HormoneSynergy® may use lawful compounded medications when individualized clinical circumstances support that choice. The decision is based on the individual patient rather than the assumption that compounded preparations are automatically safer or more effective, or that commercially available preparations are automatically preferable in every clinical situation.

Treatment Options and Routes of Administration

Hormone therapy can be delivered through several routes. Each route has its own benefits, limitations, pharmacokinetics, convenience factors, monitoring needs, and potential risks.

Options may include:

• Transdermal estradiol patches or gels
• Oral micronized progesterone
• Local vaginal estrogen preparations
• FDA-approved testosterone gels or injections for appropriately diagnosed men
• Carefully dosed testosterone therapy for selected women
• Custom-compounded creams, capsules, or other preparations
• Implanted hormone pellets for selected women who prefer this route after informed discussion

Route selection should not be reduced to a hierarchy in which one method is assumed to be best for everyone. A transdermal preparation provides dose flexibility and can be stopped easily. Oral medications may be convenient for some patients. Local vaginal treatment can deliver therapy directly to genitourinary tissues with low systemic exposure. Pellet therapy offers extended delivery without daily or weekly administration but is less readily adjusted after insertion.

HormoneSynergy® discusses these differences with patients so that the method chosen reflects both the available medical evidence and the patient's clinical circumstances and preferences.

How Long Should Hormone Therapy Continue?

There is no single duration that is appropriate for every patient.

For women, menopausal hormone therapy may be used for symptom management or other recognized indications, with periodic reassessment of benefits, risks, dose, route, and continued need. Major menopause organizations no longer recommend automatically stopping hormone therapy simply because a woman reaches a predetermined age.

The Menopause Society states that continuation beyond age 65 can be reasonable for selected women with persistent symptoms or other appropriate indications after individualized risk assessment and counseling.

Starting systemic menopausal hormone therapy for the first time at an older age is a different clinical question from continuing appropriately selected therapy that began closer to menopause. Age, years since menopause, dose, route, and underlying cardiovascular risk remain relevant.

For men, testosterone therapy should continue while the indication remains appropriate, treatment is providing meaningful benefit, and monitoring does not identify unacceptable adverse effects or contraindications.

Laboratory Testing Is Useful, but It Does Not Replace Clinical Judgment

Hormone therapy should not be reduced to pursuing a laboratory number in isolation.

In women undergoing a typical menopausal transition, the diagnosis is often clinical and repeated hormone measurements are not routinely necessary to determine menopausal status. Laboratory testing becomes more useful when the diagnosis is uncertain, symptoms are atypical, another endocrine condition is suspected, premature ovarian insufficiency is being considered, or testosterone or another therapy requires monitoring.

Pellet therapy is one situation in which laboratory assessment may be useful as part of ongoing monitoring, particularly when testosterone is used and there is a need to evaluate exposure, symptoms, or the possibility of supraphysiologic levels.

For men, testosterone testing is central to diagnosis because symptoms alone are not sufficient. Testosterone deficiency should generally be confirmed with repeated early-morning measurements before treatment begins.

Laboratory results are most useful when interpreted alongside symptoms, treatment response, medical history, physical findings, and the route of therapy being used.

Hormones Within a Broader Longevity Strategy

Hormone therapy can improve important symptoms and physiological functions in appropriately selected patients, but it does not replace management of the other factors that strongly influence long-term health.

Blood pressure, ApoB, lipoprotein(a), insulin resistance, visceral fat, skeletal muscle, bone health, physical activity, sleep apnea, smoking, alcohol, nutrition, and cardiorespiratory fitness remain relevant regardless of hormone status.

This is why HormoneSynergy® integrates hormone care with Preventive Cardiology, Metabolic Health, Body Composition, Brain Health & Cognitive Longevity, and Sleep and Recovery.

Longevity Medicine Resources

Selected Evidence and Guidance

• U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. February 12, 2026.
• The Menopause Society. Hormone Therapy.
• American College of Obstetricians and Gynecologists. Hormone Therapy for Menopause.
• American College of Obstetricians and Gynecologists. Compounded Bioidentical Menopausal Hormone Therapy. Clinical Consensus No. 6. Reaffirmed 2026.
• Endocrine Society. Statement on Testosterone Replacement Therapy. July 16, 2026.
• Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867.
• Bruno J, Shaw JS, Hosseini SMH, et al. Association Between Menopausal Hormone Therapy and Alzheimer Disease Neuropathology. Neurology. 2026;107(5):e218413.

Frequently Asked Questions

What does “bioidentical” mean?

Bioidentical means that the hormone has the same molecular structure as a hormone produced naturally in the human body. Bioidentical hormones can be FDA-approved prescription products or custom-compounded preparations.

Are compounded hormones the same as bioidentical hormones?

No. Some compounded hormones are bioidentical, but many FDA-approved medications are also bioidentical. The term describes molecular structure rather than whether the medication was commercially manufactured or compounded.

Does HormoneSynergy® offer pellet therapy for women?

Yes. Pellet therapy is one of several hormone-delivery options available to appropriately selected women at HormoneSynergy®. Dr. Kathryn Retzler has many years of clinical experience providing pellet therapy and uses that experience in patient selection, dosing, counseling, monitoring, and follow-up. The benefits and limitations of pellets are discussed alongside transdermal, oral, vaginal, compounded, and other treatment options.

What are the advantages of pellet therapy?

Pellets provide extended hormone delivery without the need for daily tablets, gels, or regularly changed patches. Some women value the convenience and consistency of this approach, particularly when they have previously responded well to pellet therapy. Because pellets are implanted and dissolve gradually, dosing cannot be adjusted as quickly after insertion as it can with a patch, gel, or oral medication.

What does ACOG say about testosterone pellets in women?

ACOG notes that implanted testosterone may improve menopause-related symptoms, but it recommends other testosterone preparations because long-term safety data remain limited and pellets cannot be readily removed after insertion. HormoneSynergy® discusses this guidance with patients considering pellet therapy and uses shared decision-making when evaluating whether the route is appropriate for the individual woman.

Are compounded bioidentical hormones safer?

Compounded hormones are not inherently safer or more effective simply because they are described as bioidentical. They can still be useful when an individualized dose, formulation, ingredient profile, or route is clinically appropriate and is not adequately addressed by commercially available products.

Do women with a uterus need progesterone with estrogen?

Women with an intact uterus who use systemic estrogen generally require adequate progesterone or another progestogen to reduce the risk of endometrial hyperplasia and endometrial cancer.

Did the FDA remove the boxed warning from hormone therapy?

In February 2026, the FDA approved labeling changes for an initial group of menopausal hormone therapy products that removed boxed-warning statements related to cardiovascular disease, breast cancer, and probable dementia. This does not mean hormone therapy is risk-free or appropriate for everyone.

Does hormone therapy prevent dementia?

Menopausal hormone therapy has not been proven to prevent dementia. Several 2026 observational studies have reported favorable associations between estrogen exposure, timing of menopause, and cognitive or Alzheimer-related outcomes, but randomized evidence remains insufficient to prescribe hormone therapy solely for dementia prevention.

Can women use testosterone?

Yes, in selected circumstances. The strongest randomized evidence is for appropriately evaluated women with hypoactive sexual desire disorder. In clinical practice, route, dose, symptoms, response, laboratory values when appropriate, and potential androgenic effects all require individualized consideration.

How is low testosterone diagnosed in men?

Diagnosis generally requires symptoms or signs consistent with testosterone deficiency together with consistently low testosterone concentrations, typically confirmed with at least two early-morning blood measurements.

Do women need to stop menopausal hormone therapy at age 65?

Not automatically. The Menopause Society does not recommend a universal age at which every woman must stop hormone therapy. Continued treatment can be considered in selected women after individualized assessment of symptoms, risks, benefits, dose, and route.

What happens during a hormone evaluation?

A hormone evaluation includes a detailed symptom and medical-history review, current medications, previous hormone use, relevant risk factors, treatment preferences, and laboratory testing when clinically appropriate. The discussion can include several delivery methods, including pellet therapy, when they are reasonable options for the individual patient.